Pathobiologic characteristics of hereditary breast cancer

Human Pathology

Volumn 29, Issue 10, 1998, Pages 1140-1144

  Lynch, Beverly J ^a   Holden, Joseph A ^a   Buys, Saundra S ^a   Neuhausen, Susan L ^a   Gaffney, David K ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

BRCA1; BRCA2; DNA topo II alpha; Hereditary breast cancer; Immunohistochemical staining

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER GRADING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FAMILIAL CANCER; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; TUMOR SUPPRESSOR GENE;

EID: 0031690463     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(98)90427-0     Document Type: Article

References (26)

1. Parker SL, Tong T, Bolden S, et al: Cancer Statistics, 1996. CA Cancer J Clin 65:5-27, 1996
2. Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71, 1994
3. Wooster R, Neuhausen SL, Mangion J, et al: Localization of breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265:2088-2090, 1994
4. Krainer M, Silva-Arrieta S, Fitzgerald MG: Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 336:1416-1421, 1997
5. Fitzgerald MG, MacDonald DJ, Krainer M, et al: Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 334:143-149, 1996
6. Porter DE, Cohen BB, Wallace MR, et al: Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg 81:1512-1515, 1994
7. Marcus JN, Watson P, Page DL, et al: Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77:697-709, 1996
8. Albano WA, Recabaren JA, Lynch HT, et al: Natural history of hereditary cancer of the breast and colon. Cancer 50:360-363, 1980
9. Eisinger F, Stoppa-Lyonnet D, Longy M, et al: Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 56:471-474, 1996
10. Breast Cancer Linkage Consortium: Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 and BRCA2 mutations and sporadic cases. Lancet 349:1505-1510, 1997
11. Karp S, Tonin PN, Begin LR, et al: Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 80:435-441, 1997
12. Thor AD, Moore DH, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992
13. Crook T, Crossland S, Crompton M, et al: p53 mutations in BRCA1-associated familial breast cancer. Lancet 350:638-639, 1997
14. Lynch BJ, Guinee DG, Holden JA: Human DNA topoisomerase II-alpha: A new marker of cell proliferation in invasive breast cancer. HUM PATHOL 28:1180-1188, 1997
15. Gasparini G, Weidner N, Bevilaqua P, et al: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12:454-466, 1994
16. Shattuck-Eidens D, McClure M, Simard J, et al: A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. JAMA 273:535-541, 1995
17. Tavitigian SV, Simard J, Rommens J, et al: The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nature Genet 12:333-337, 1996
18. Contesso G, Mouriesse H, Friedman S, et al: The importance of histologic grading in long-term prognosis of breast cancer: A study of 1010 patients, uniformly treated at the Institute Gustave Roussy. J Clin Oncol 5:1378-1386, 1987
19. MacGrogan G, Mauriac L, Durand M, et al: Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erb-2, Mib1, pS2 and GST. Br J Cancer 74:1458-1465, 1996
20. Charpin C, Garcia S, Bouvier C, et al: Quantitative immunocytochemical assays on frozen sections of p53. Am J Clin Pathol 106:640-646, 1996
21. Brambilla E, Negoescu A, Gazzeri S, et al: Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 149:1941-1952, 1996
22. Weidner N, Folkman J, Pozza F, et al: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1887, 1992
23. Dawson-Saunders B, Trapp RG: Basic and Clinical Biostatistics. Norwalk, CT, Appleton and Lange, 1994
24. Gaffney DK, Lewis CM, Cannon-Albright L, et al: Proc Int Assoc Breast Cancer Res 29, 1996
25. Bignon YJ, Fonck Y, Chassagne MC: Histoprognostic grade in tumours from families with hereditary predisposition to breast cancer. Lancet 346:258, 1995
26. Gamel JW, Meyer JS, Province MA: Proliferative rate by S-phase measurement may affect cure of breast carcinoma. Cancer 76:1009-1018, 1995